| abstract |
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptor subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and . Specifically, such diseases are disorders of the central nervous system that are selected from the group that includes anxiety, schizophrenia, migraine, depression, and epilepsy. The invention also relates to pharmaceutical compositions and processes for the preparation of such compounds and compositions, and to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. |